Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

BACKGROUND: Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating agent, decitabine, improves progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Wang, Chunmeng, Li, Xiang, Dong, Liang, Yang, Qingming, Chen, Meixia, Shi, Fengxia, Brock, Malcolm, Liu, Miao, Mei, Qian, Liu, Jiejie, Nie, Jing, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025784/
https://www.ncbi.nlm.nih.gov/pubmed/33820822
http://dx.doi.org/10.1136/jitc-2021-002347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025784/
https://www.ncbi.nlm.nih.gov/pubmed/33820822
http://dx.doi.org/10.1136/jitc-2021-002347

Ejemplares similares